Mechanisms of cancer therapeutic resistance via Rho-mediated epithelial-mesenchymal transition
| Project/Area Number |
26860244
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Human pathology
|
|---|
| Research Institution | Jichi Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2016: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 前立腺癌 / 乳癌 / 治療抵抗性 / 上皮間葉転換 / 細胞老化 / 抗酸化反応 / SASP |
|---|
| Outline of Final Research Achievements |
Recurrence of hormone-unresponsive cancer is a serious problem in prostate and breast cancer. In this study, we demonstrate that Rho-mediated epithelial-mesenchymal transition (EMT) is stimulated not only in endocrine therapy resistance of prostate cancer, but also in chemotherapy resistance of breast cancer. We also demonstrate that, in hormone-responsive cancer cells, cellular senescence and anti-oxidant response are stimulated by hormone ablation. Senescent phenotypes are reduced by treatment of either anti-oxidant reagent of N-Acetyl-L-cysteine or TGF beta. These results suggest that survived cancer cells may utilize various tools such as EMT, cellular senescence, senescence-associated secretory phenotype, and anti-oxidant response, resulting in therapy resistance.
|
Report
(4 results)
Research Products
(14 results)
